Study for Recalcitrant Age Related Macular Degeneration
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
50 Patients with recalcitrant exudative age-related macular degeneration with a history of
retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and
subsequently treated with ranibizumab 2.0mg, who are incomplete responders to 2.0mg of
ranibizumab.